After the offer period of the public tender offer of Danaher Corporation ("Danaher") for all publicly held registered shares of Nobel Biocare Holding AG ("Nobel Biocare") ("Offer") expired on November 14, 2014 at 4 p.m. CET ("Offer Period"), Danaher today has released the provisional notice of the interim result.
Danaher has reported that according to a provisional calculation, until the end of the Offer Period a total of 72,001,022 Nobel Biocare shares, corresponding to 60.97% of the 118,095,706 Nobel Biocare shares to which the Offer relates (success rate), were tendered under the public tender offer. Taking into account the 5,688,824 Nobel Biocare shares, which Danaher and the persons acting in concert with Danaher held as per September 26, 2014 as well as the 19,506,788 Nobel Biocare shares which were acquired by Danaher and the persons acting in concert with Danaher outside the Offer, at the end of the Offer Period Danaher and the persons acting in concert with Danaher economically held a total of 97,196,634 Nobel Biocare shares, corresponding to 78,52% of all listed Nobel Biocare shares (participation rate).
Therewith, more than the 67%of all issued Nobel Biocare shares which are required to meet one of Danaher's key offer conditions were tendered by the end of the Offer Period.
Danaher has confirmed that in case all relevant conditions are fulfilled, the additional acceptance period for the Offer will start on November 21, 2014, and is expected to last until December 4, 2014, at 4 p.m. CET. The Board of Directors of Nobel Biocare recommends to its shareholders to accept the Offer.
Nobel Biocare has published the offer documents on
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.